lgbtDB

(Q29504)

Statements

title
Safe and supportive prescribing in transgender and non-binary patients with cancer. (English)
1 reference
stated in
PubMed
abstract
Global prevalence rates for transgender individuals vary with estimates ranging from 0.3% to 1%, translating to a potential global population of 24.3 million to 81 million. (English)
series ordinal
1
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
It is estimated that one in two people will develop cancer in their lifetime. (English)
series ordinal
2
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
Gender-affirming hormone therapy (GAHT) is a common medical intervention for transgender and non-binary individuals. (English)
series ordinal
3
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
GAHT requires careful consideration for concurrent medical care due to potential drug interactions and physiological changes. (English)
series ordinal
4
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
A multi-disciplinary team with expertise in transgender health, oncology and pharmacy met to develop a document summarizing current knowledge on the topic for practical use. (English)
series ordinal
5
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
The team included trans and non-binary authors who shaped the document's language and focus. (English)
series ordinal
6
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
The document gives a status update on the current understanding of GAHT and how this may intersect with the safe prescribing of systemic anti-cancer therapies (SACT). (English)
series ordinal
7
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
The document underwent multiple review stages including internal review, review by the British Oncology Pharmacy Association (BOPA) EDI Subcommittee and, finally, BOPA Executive Committee review and final approval. (English)
series ordinal
8
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
Key recommendations of this document include the use of inclusive and effective communication, vigilant monitoring of kidney function and cardiovascular health, and considerations for hormone receptor-positive cancers. (English)
series ordinal
9
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
The document also recognizes the multidisciplinary nature of transgender healthcare and where this relates to social prescribing. (English)
series ordinal
10
copyright statement
© 2024 British Pharmacological Society. (English)
date copyrighted
2024
rights holder
British Pharmacological Society
1 reference
stated in
PubMed
date published
October 2024
1 reference
stated in
PubMed
date issued
October 2024
1 reference
stated in
PubMed
volume
90
1 reference
stated in
PubMed
issue
10
1 reference
stated in
PubMed
page(s)
2401-2408
1 reference
stated in
PubMed
page start
2401
1 reference
stated in
PubMed
page end
2408
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q29504&oldid=181009"